I 
119TH CONGRESS 
1ST SESSION H. R. 4030 
To amend the Public Health Service Act to authorize the Secretary of Health 
and Human Services to address priority substance use disorder and 
serious mental illness treatment needs through long-acting injectable 
medications, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 17, 2025 
Mr. DUNN of Florida (for himself, Mr. SOTO, and Mr. BEAN of Florida) intro-
duced the following bill; which was referred to the Committee on Energy 
and Commerce 
A BILL 
To amend the Public Health Service Act to authorize the 
Secretary of Health and Human Services to address pri-
ority substance use disorder and serious mental illness 
treatment needs through long-acting injectable medica-
tions, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Treatment Continuity 
Act of 2025’’. 
VerDate Sep 11 2014 
00:50 Jun 26, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4030.IH
H4030
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 2. PRIORITY SUBSTANCE USE DISORDER AND SERI-
OUS MENTAL ILLNESS TREATMENT NEEDS 
OF REGIONAL AND NATIONAL SIGNIFICANCE. 
(a) IN GENERAL.—Section 509 of the Public Health 
Service Act (42 U.S.C. 290bb–2) is amended— 
(1) in the section heading, by inserting ‘‘AND 
SERIOUS MENTAL ILLNESS’’ after ‘‘SUBSTANCE 
USE DISORDER’’; 
(2) in subsection (a)— 
(A) in the matter preceding paragraph (1), 
by inserting ‘‘and serious mental illness’’ after 
‘‘substance use disorder’’; and 
(B) by striking paragraphs (1) through (3) 
and inserting the following: ‘‘ 
‘‘(1) access to long-acting injectable medications 
that are approved by the Food and Drug Adminis-
tration for the treatment of individuals with sub-
stance use disorders or serious mental illness; 
‘‘(2) lab testing and supportive counseling for 
substance use disorder and serious mental illness; 
and 
‘‘(3) training on the use of long-acting 
injectable medications for the purposes described in 
paragraph (1), in combination with associated clin-
ical services such as counseling.’’; 
(3) in subsection (b)— 
VerDate Sep 11 2014 
00:50 Jun 26, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4030.IH
H4030
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(A) in the subsection heading, by inserting 
‘‘AND SERIOUS MENTAL ILLNESS’’ after ‘‘SUB-
STANCE USE DISORDER’’; and 
(B) in paragraphs (1) and (2), by inserting 
‘‘and serious mental illness’’ after ‘‘substance 
use disorder’’; 
(4) by striking subsections (d) and (e) and in-
serting the following: 
‘‘(d) ANNUAL REPORT
TO CONGRESS.—Not later 
than 1 year after the date of enactment of the Treatment 
Continuity Act of 2025, and annually thereafter during 
the term of the program under this section, the Secretary 
shall transmit to Congress a report on the outcomes of 
such program, including completed or substantial progress 
toward treatment requirements based on clinician assess-
ment.’’; and 
(5) by redesignating subsection (f) as sub-
section (e). 
(b) APPLICABILITY.—The amendments made by this 
section shall apply to grants made under section 509 of 
the Public Health Service Act after the date of the enact-
ment of this Act. 
Æ 
VerDate Sep 11 2014 
00:50 Jun 26, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H4030.IH
H4030
kjohnson on DSK7ZCZBW3PROD with $$_JOB